本文選題：加味六君子湯 + 非小細胞肺癌�。� 參考：《黑龍江中醫(yī)藥大學》2017年碩士論文

【摘要】：目的:通過加味六君子湯聯(lián)合TP方案及單獨TP方案對非小細胞肺癌治療的臨床療效對比觀察,探討加味六君子湯的治療作用。方法:收集2016年1月—2017年1月期間在黑龍江中醫(yī)藥大學附屬第一醫(yī)院和哈爾濱醫(yī)科大學附屬腫瘤醫(yī)院就診的原發(fā)性非小細胞肺癌(NSCLC)患者為觀察對象,符合納入標準,且中醫(yī)辨證為肺脾氣虛型者60例。對照組及治療組各30例。所有患者均接受常規(guī)化療治療,若出現(xiàn)副反應采取針對性措施進行治療。治療組除了接受化療治療之外,還需口服加味六君子湯,服藥時間從化療前三天持續(xù)到停止化療后的一周內(nèi)。在治療之前記錄患者病理分型,對其進行TNM國際分期、卡氏評分、中醫(yī)證候評價。結(jié)束治療后觀察療效,再次進行卡氏評分以及中醫(yī)證候評價。結(jié)果:1.在改善中醫(yī)證候積分方面,治療組優(yōu)于對照組,組間對比具有顯著性差異(P0.05)。2.在提高卡氏評分方面,治療組優(yōu)于對照組,組間對比具有顯著性差異(P0.05)。3.在穩(wěn)定瘤體方面,兩組患者經(jīng)治療后均無CR病例,治療組與對照組的有效率均為6.7%,治療組穩(wěn)定率為83.33%,高于對照組的76.67%,兩組間比較無統(tǒng)計學意義(P0.05),但治療組在穩(wěn)定瘤體方面略有優(yōu)勢。4.在降低腫瘤標記物CEA、CY211水平方面,兩組治療后相比較,無顯著意義(P0.05),但是治療組較對照組下降明顯。5.在不良反應方面,兩組均未見明顯的毒副反應。結(jié)論:1.加味六君子湯聯(lián)合TP方案可以降低非小細胞肺癌患者的中醫(yī)證候積分,提高卡氏評分,提高生活質(zhì)量;2.加味六君子湯聯(lián)合TP方案具有穩(wěn)定瘤體的作用;3.加味六君子湯聯(lián)合TP方案可以降低腫瘤標記物CEA、CY211水平;4.加味六君子湯聯(lián)合TP方案不良反應輕微,安全可靠。
[Abstract]:Objective: To compare the clinical efficacy observation of the treatment of non-small cell lung cancer by Modified Decoction of six noble drugs combined with TP regimen and TP regimen alone, to investigate the therapeutic effects of Modified Decoction of six noble drugs. Methods: from January 2016 to January 2017 in the First Affiliated Hospital of Heilongjiang University Of Chinese Medicine and Cancer Hospital Affiliated to Harbin Medical University for treatment of primary non-small cell lung cancer (NSCLC) patients the object, in accordance with the inclusion criteria, and TCM syndrome differentiation of lung and spleen deficiency in 60 cases. The control group and the treatment group with 30 cases in each group. All patients received conventional chemotherapy treatment, if adverse reactions take targeted treatment measures. The treatment group in addition to chemotherapy treatment, also need oral modified decoction of six noble drugs, medication time from three days before chemotherapy to stop after chemotherapy within a week. The pathological type were recorded before treatment, the TNM of the international stage, calmetii Score, TCM syndrome efficacy evaluation. After the end of treatment, again and Karnofsky score of TCM Syndrome Evaluation. Results: 1. points in improving TCM syndrome, the treatment group than the control group, the comparison between the two groups had significant difference (P0.05) of.2. in improving the Karnofsky score, the treatment group than the control group the comparison between the two groups, with significant difference (P0.05) of.3. on the stability of the tumor, two groups of patients after treatment, there were no CR cases, the effective rate of the treatment group and the control group was 6.7%, the treatment group rate of 83.33%, higher than 76.67% in the control group, there was no significant difference between the two groups (P0.05), but the treatment group in the stable tumor advantage of.4. in reducing tumor markers CEA, CY211 level, the two groups after treatment compared with no significant difference (P0.05), but the treatment group decreased significantly than the control group.5. in terms of adverse reactions, two groups were no obvious adverse reaction Conclusion: 1.. Modified Decoction of six noble drugs combined with TP regimen can reduce the TCM syndromes in patients with small cell lung cancer, improve Karnofsky score, improve the quality of life; 2. Modified Decoction of six noble drugs combined with TP regimen has a stable tumor effect; 3. Modified Decoction of six noble drugs combined with TP chemotherapy can reduce tumor markers CEA the level of CY211; the adverse reactions of the 4. Modified Decoction of six noble drugs combined with TP regimen in mild, safe and reliable.

【學位授予單位】：黑龍江中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關(guān)期刊論文 前10條

1 張建軍;胡春玲;;中藥黨參研究的現(xiàn)代進展[J];甘肅高師學報;2017年03期

2 鞠康;趙利敏;;前胡化學成分及其藥理作用研究進展[J];內(nèi)蒙古中醫(yī)藥;2017年03期

3 梁欣妍;丁筑紅;;薏苡仁油對消化系統(tǒng)腫瘤的藥理作用及臨床應用[J];實用醫(yī)學雜志;2017年01期

4 張恒;饒坤林;向韓;;橙皮苷藥理活性研究進展[J];中南藥學;2016年10期

5 劉文亞;顧媛媛;鞏穎;;生半夏抗腫瘤作用初探[J];臨床合理用藥雜志;2016年20期

6 岳美穎;;茯苓主要藥理作用及臨床應用[J];亞太傳統(tǒng)醫(yī)藥;2016年07期

7 逯雙;楊培民;曹廣尚;;白花蛇舌草活性成分多糖與黃酮研究進展[J];中國中醫(yī)藥信息雜志;2016年03期

8 岳美穎;潘媛;敖慧;;白術(shù)化學、藥理與臨床研究進展[J];亞太傳統(tǒng)醫(yī)藥;2016年05期

9 陳曲;;化療聯(lián)合貝伐珠單抗治療非小細胞肺癌的療效觀察[J];中國醫(yī)藥指南;2016年03期

10 鄭末;姜忠敏;;連翹苷對Lewis肺癌VEGF和內(nèi)皮抑素表達的影響[J];中國病理生理雜志;2016年01期

，

本文編號：1758327